RSV—respiratory syncytial virus—is a common infection that causes cold-like symptoms but can become very severe in young children and is the leading cause of hospitalization for babies under 1. Dr. Ruth Karron, director of the Johns Hopkins Vaccine Initiative, talks with Dr. Josh Sharfstein about two new products, a vaccine for pregnant people and an antibody treatment for babies, that could substantially lower the rates of severe infections among children. However, the rollout has been slow and people may still have a hard time getting them for their children as RSV season kicks into gear.